NRX Pharmaceuticals, Inc. (NRXP): Total Liabilities
$28.89M
As of 2025-12-31
$34.33M
As of 2026-06-30
+16.2%
3-year compound annual growth
-9.2%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $28.89M | +7.5% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $26.87M | +41.1% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $19.05M | +3.5% | 2025-03-14, Balance as of period end |
| 2022-12-31 | $18.41M | +54.4% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $11.92M | -74.5% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $46.71M | n/m | 2022-03-31, Balance as of period end |
| 2019-12-31 | $2.57M | +104.7% | 2021-05-14, Balance as of period end |
| 2018-12-31 | $1.26M | n/m | 2020-03-30, Balance as of period end |
| 2017-12-31 | $93.2K | n/a | 2019-03-15, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $28.89M | +7.5% |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $1.10M | +34.7% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $128.86M | +21.9% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | $37.17M | +21.3% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $17.11M | -48.4% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $2.42M | -6.4% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $13.04M | -6.5% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $4.59M | +24.9% |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $4.11M | -57.1% |
Compare NRXP, ATXI, NWBO, CPMD side by side · Screen every company in Pharmaceutical Preparations ↗